Study reveals how a blood biomarker tracks response to lecanemab in early Alzheimer's disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by changes involving amyloid-beta and tau proteins in the brain. Lecanemab is an anti-amyloid therapy approved for people with early AD that has been shown to slow disease progression. However, treatment responses can vary among individuals, creating a need for accessible ways to monitor biological changes during therapy.

≈